--()--Dell:
WHAT
The team of parents,
genetic and translational medicine scientists and pediatric oncologists
trailblazing personalized medicine in the treatment of deadly pediatric
cancers is convening in Austin to discuss the status of the world’s
first personalized medicine clinical trial for pediatric cancer and plan
next steps at the NMTRC
Symposium 2012. Neuroblastoma affects 1 in 100,000 children and is
responsible for 1 in 7 pediatric cancer deaths.
WHO
Parents, advocates,
oncologists from the Neuroblastoma
and Medulloblastoma Translational Research Consortium (NMTRC) and
biomedical researchers from the Translational
Genomics Research Institute (TGen), who are using high
performance computing and cloud technology from Dell to identify
targeted treatments based on the specific genetic vulnerabilities of
each child’s tumor—an approach that could be used to treat all pediatric
and adult cancers in the future.
WHY
Personalized
medicine—treatment based on the specific vulnerabilities of each tumor—
is overcoming longstanding barriers to treatment of pediatric cancer.
There has been only one new treatment for pediatric cancer approved by
the FDA since the 1980s, compared to 50 treatments approved for adult
cancer in this same timeframe. As a result, pediatric oncologists use
treatments designed for adults to treat children, with toxic side
effects that are frequently as physically detrimental to the child as
the cancer itself.
WHEN
The following events will
be available via live-stream:
May 16
1-2 pm CT: Keynote:
“Molecular-Profiling for Optimized Precision Therapy,”
Dr.
Timothy Triche, University of Southern California/ Children’s
Hospital Los Angeles
2-4 pm CT: Panel Discussion: “Kids Cloud: Access to Data
Boundaries”
Dr.
Melinda Merchant - National Cancer Institute
Dr.
Gary Marchant - Arizona State University
Nancy Goodman - Kids
V. Cancer Foundation
Patrick Lacey - Friends
of Will Foundation
Andy Mikulak - Max’s
Ring of Fire Foundation
Dr.
Giselle Sholler - Van Andel Institute
Dr.
Spyro Mousses - Translational Genomics Research Institute
Dr.
James Coffin - Dell
WHERE
Participate and join the
conversation via the #HealthCloud
hashtag on Twitter.
Tune in via Live-Stream here: http://www.fittotweet.com/live/nmtrc/.


